Literature DB >> 9366889

Modeling valuations for EuroQol health states.

P Dolan1.   

Abstract

OBJECTIVES: It has become increasingly common for preference-based measures of health-related quality of life to be used in the evaluation of different health-care interventions. For one such measure, The EuroQol, designed to be used for these purposes, it was necessary to derive a single index value for each of the 243 health states it generates. The problem was that it was virtually impossible to generate direct valuations for all of these states, and thus it was necessary to find a procedure that allows the valuations of all EuroQol states to be interpolated from direct valuations on a subset of these.
METHODS: In a recent study, direct valuations were elicited for 42 EuroQol health states (using the time trade-off method) from a representative sample of the UK population. This article reports on the methodology that was adopted to build up a "tariff" of EuroQol values from this data.
RESULTS: A parsimonious model that fits the data well was defined as one in which valuations were explained in terms of the level of severity associated with each dimension, an intercept associated with any move away from full health, and a term that picked up whether any dimension in the state was at its most severe level.
CONCLUSIONS: The model presented in this article appears to predict the values of the states for which there are direct observations and, thus, can be used to interpolate values for the states for which no direct observations exist.

Entities:  

Mesh:

Year:  1997        PMID: 9366889     DOI: 10.1097/00005650-199711000-00002

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  1467 in total

1.  Sample size calculations in studies using the EuroQol 5D.

Authors:  M Roset; X Badia; N E Mayo
Journal:  Qual Life Res       Date:  1999-09       Impact factor: 4.147

2.  Comparison of the Health Utilities Index Mark 3 (HUI3) and the EuroQol EQ-5D in patients treated for intermittent claudication.

Authors:  J L Bosch; M G Hunink
Journal:  Qual Life Res       Date:  2000       Impact factor: 4.147

3.  Assessment of quality of life in lung transplantation using a simple generic tool.

Authors:  A C Anyanwu; A McGuire; C A Rogers; A J Murday
Journal:  Thorax       Date:  2001-03       Impact factor: 9.139

4.  Responsiveness of the EuroQol in breast cancer patients undergoing high dose chemotherapy.

Authors:  B Conner-Spady; C Cumming; J M Nabholtz; P Jacobs; D Stewart
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

5.  Swedish population health-related quality of life results using the EQ-5D.

Authors:  K Burström; M Johannesson; F Diderichsen
Journal:  Qual Life Res       Date:  2001       Impact factor: 4.147

6.  Validating Performance of a Hospital Discharge Planning Decision Tool in Community Hospitals.

Authors:  Diane E Holland; Cheryl Brandt; Paul V Targonski; Kathryn H Bowles
Journal:  Prof Case Manag       Date:  2017 Sep/Oct

7.  The significance of frailty in the relationship between socioeconomic status and health-related quality of life in the Korean community-dwelling elderly population: mediation analysis with bootstrapping.

Authors:  Ho-Joong Kim; Saejong Park; Soo-Hyun Park; Young Woo Heo; Bong-Soon Chang; Choon-Ki Lee; Jin S Yeom
Journal:  Qual Life Res       Date:  2017-08-03       Impact factor: 4.147

8.  EQ-5D-5L is More Responsive than EQ-5D-3L to Treatment Benefit of Cataract Surgery.

Authors:  Mihir Gandhi; Marcus Ang; Kelvin Teo; Chee Wai Wong; Yvonne Chung-Hsi Wei; Rachel Lee-Yin Tan; Mathieu F Janssen; Nan Luo
Journal:  Patient       Date:  2019-08       Impact factor: 3.883

9.  Cost-effectiveness of mirabegron compared to tolterodine ER 4 mg for overactive bladder in Canada.

Authors:  Sender Herschorn; Jameel Nazir; Barbara Ramos; Zalmai Hakimi
Journal:  Can Urol Assoc J       Date:  2017 Mar-Apr       Impact factor: 1.862

10.  Impact of vertebral deformities, osteoarthritis, and other chronic diseases on quality of life: a population-based study.

Authors:  N M van Schoor; J H Smit; J W R Twisk; P Lips
Journal:  Osteoporos Int       Date:  2004-10-12       Impact factor: 4.507

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.